Glox Therapeutics is set to receive a share of the £3m ($3.67m) Collaborative Discovery Programme (CDP) funding introduced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The ...
GLASGOW, Scotland--(BUSINESS WIRE)--Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment ...
GLASGOW, Scotland, November 20, 2024--(BUSINESS WIRE)--Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today ...
£500K grant to advance discovery and development of effective precision antibiotics targeting antimicrobial-resistant lung infections in people with cystic fibrosis Programme delivered by CF AMR ...
Glox Therapeutics has announced it has secured £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria to fight against antimicrobial resistance (AMR ...
Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria. The Company will use the funding to ...
Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced the appointment of Dr Michael Murray as Chair of ...
GLASGOW, Scotland--(BUSINESS WIRE)--Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has been ...
Expanded team to support development and commercialisation of precision antibiotics to help overcome antimicrobial resistance Glox Therapeutics, a company pioneering the development of precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback